Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organogenesis HoldingsORGO -0.40%68 Debt-to-Equity is 0.19 as of Mar. 2026, which is 59% below its 10-year median of 0.46. GuruFocus rates ORGO with a GF Score™ of 68/100 and a GF Value™ of $2.96 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 813 Drug Manufacturers companies, Organogenesis Holdings ranks better than 59.53% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Organogenesis Holdings's Debt-to-Equity or its related term are showing as below:
ORGO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -11.96 Med: 0.46 Max: 7.87
Current: 0.19
During the past 11 years, the highest Debt-to-Equity Ratio of Organogenesis Holdings was 7.87. The lowest was -11.96. And the median was 0.46.
ORGO's Debt-to-Equity is ranked better than 59.53% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ORGO: 0.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Organogenesis Holdings Debt-to-Equity Related Terms
Organogenesis Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORGO vs AKBA, TKNO, EBS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (ORGO) has a Debt-to-Equity of 0.19 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Organogenesis Holdings and its competitors. This is 59% below median its historical median of 0.46. According to the industry distribution chart, Organogenesis Holdings ranks #329 out of 813 companies in the Drug Manufacturers industry, placing it in the top 40.5%.
Is Organogenesis Holdings' Debt-to-Equity too high?
Organogenesis Holdings' current Debt-to-Equity of 0.19 is 59% below median its 10-year median of 0.46. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Organogenesis Holdings' value of 0.19 is 29.6% below this industry median. Based on the distribution chart, Organogenesis Holdings ranks #329 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Debt-to-Equity compare to AKBA and TKNO?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #329 out of 813 companies for Debt-to-Equity. This puts Organogenesis Holdings in the upper half of its industry. The industry median Debt-to-Equity is 0.27. Organogenesis Holdings' value of 0.19 is 29.6% below this benchmark. While the company's 10-year median is 0.46 vs. the industry median of 0.27, Organogenesis Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Debt-to-Equity of 0.19 is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Debt-to-Equity is 0.19, which is 59% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.96, compared to a current price of $2.52 — trading 14.9% below its estimated fair value. The current Debt-to-Equity is 0.19, which is 59% below median its 10-year median of 0.46 and 29.6% below the Drug Manufacturers industry median of 0.27. Organogenesis Holdings' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Debt-to-Equity is 0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (ORGO) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of $2.52 is trading 14.9% below its estimated GF Value™ of $2.96.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for ORGO:
Debt-to-Equity: 0.19 (59% below median its 10-year median of 0.46)
GF Value™: $2.96 vs. price of $2.52 (14.9% below fair value)
Industry Position: 29.6% below the Drug Manufacturers median (#329 of 813)
No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
68GF Score
Get the complete analysis for ORGO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGO has been successfully added to your 
